ArticleOncoTargets and therapy2017
Ezh2, a novel target in detection and therapy of breast cancer.
Article in OncoTargets and therapy, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Comparative analysis of EZH2, p16 and p53 expression in uterine carcinosarcomas.Pathology oncology research : POR · 2023Article
- Upregulated hsa_circ_0000129 expression promotes proliferation and migration of breast cancer cells.Oncology letters · 2021Article
- Downregulation of histone-lysine N-methyltransferase EZH2 inhibits cell viability and enhances chemosensitivity in lung cancer cells.Oncology letters · 2021Article
- Robust expression of EZH2 in endocervical neoplastic lesions.Virchows Archiv : an international journal of pathology · 2019Article
- Comprehensive analysis of the GATA transcription factor gene family in breast carcinoma using gene microarrays, online databases and integrated bioinformatics.Scientific reports · 2019Article
- Role of cellular reprogramming and epigenetic dysregulation in acquired chemoresistance in breast cancer.Cancer drug resistance (Alhambra, Calif.) · 2019Review
- Overview on Epigenetic Re-programming: A Potential Therapeutic Intervention in Triple Negative Breast CancersAsian Pacific journal of cancer prevention : APJCP · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.